Indivior PLC (INDV) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

22/25

Growth 5 Margin 5 Expansion 5 Platform 2 Financial 5

latest quarter score

Earnings Reports

22
Indivior (INDV) Q2 2026: $125M Synergy Target Unlocks CNS Growth Platform in Supernus Merger
August 04, 2026
17
Indivior (INDV) Q1 2026: Sublocade Revenue Jumps 32% as EBITDA Margin Hits 51%
April 30, 2026
19
Indivior (INDV) Q4 2025: Sublocade Dispense Units Up 12% as EBITDA Margin Expands 500bps
February 26, 2026
15
Indivior (INDV) Q3 2025: $150M Cost Cuts Reshape Operating Model Ahead of Phase Two
October 30, 2025
12
Indivior (INDV) Q2 2025: $100M Cost Savings Offset Suboxone Price Erosion, Sublocade Share Holds
July 06, 2025
11
Indivior (INDV) Q1 2025: 14% Patient Growth Masks 6% Revenue Decline Amid Justice System Funding Challenges
April 24, 2025

Browse all companies